Structure-guided engineering of peptide-based NLRP3 inflammasome inhibitors for myelodysplastic syndromes (MDS)
US-12565523-B2 · Mar 3, 2026 · US
This page is not indexed by search engines while we improve data quality.
List Alan patents
List Alan is listed as an inventor on 29 patents in our database. Major assignees and classification codes are summarized below.
| Metric | Value |
|---|---|
| Inventor | List Alan |
| Total patents | 29 |
| First publication | Dec 3, 2015 |
| Latest publication | Mar 3, 2026 |
Notable patents
Publications ranked by popularity score, then publication date.
Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors
US-2025257065-A1 · Aug 14, 2025 · US
Small molecule pyrin-domain targeted NLRP3 inflammasome inhibitors
US-12319685-B2 · Jun 3, 2025 · US
Stapled peptides as pyrin-domain targeted nlrp3 inflammasome inhibitors
US-2025115641-A1 · Apr 10, 2025 · US
Stapled H2 pyrin peptides
US-12077608-B2 · Sep 3, 2024 · US
Structure-guided engineering of peptide-based nlrp3 inflammasome inhibitors for myelodysplastic syndromes (mds)
US-2022324927-A1 · Oct 13, 2022 · US
Chimeric tim-3 fusion protein
US-2022144897-A1 · May 12, 2022 · US
TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS
US-2022143193-A1 · May 12, 2022 · US
Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors
US-2022098188-A1 · Mar 31, 2022 · US
PD1 and PDL-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
US-11287428-B2 · Mar 29, 2022 · US
Recent patents
Latest publications not already listed above.
Tlr9-targeted therapeutics
US-2022041682-A1 · Feb 10, 2022 · US
TLR9 targeted therapeutics
US-11123435-B2 · Sep 21, 2021 · US
Stapled peptides as pyrin-domain targeted nlrp3 inflammasome inhibitors
US-2021238228-A1 · Aug 5, 2021 · US
Pd1 and pdl-1 expression during progression from myelodysplastic syndrome to acute myelogenous leukemia
US-2021239703-A1 · Aug 5, 2021 · US
Chimeric tim-3 fusion protein
US-2021024582-A1 · Jan 28, 2021 · US
Icariin derivatives
US-2020354331-A1 · Nov 12, 2020 · US
Inflammasome activation in myelodysplastic syndromes
US-10688077-B2 · Jun 23, 2020 · US
Targeted sensitization of non-del(5q) malignant cells
US-10682417-B2 · Jun 16, 2020 · US
Icariin and icaritin derivatives
US-2020115358-A1 · Apr 16, 2020 · US
RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
US-10612097-B2 · Apr 7, 2020 · US
Tlr9 targeted therapeutics
US-2019192669-A1 · Jun 27, 2019 · US
TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS
US-2018369396-A1 · Dec 27, 2018 · US
Targeted sensitization of non-del(5q) malignant cells
US-9956294-B2 · May 1, 2018 · US
Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds
US-2018073078-A1 · Mar 15, 2018 · US
Inflammasome activation in myelodysplastic syndromes
US-2018050011-A1 · Feb 22, 2018 · US
RNF41 as a biomarker predicting response to lenalidomide in non-del(5q) MDS
US-9738933-B2 · Aug 22, 2017 · US
Icariin derivatives
US-2017044127-A1 · Feb 16, 2017 · US
TARGETED SENSITIZATION OF NON-DEL(5q) MALIGNANT CELLS
US-2015343078-A1 · Dec 3, 2015 · US
Rnf41 as a biomarker predicting response to lenalidomide in non-del(5q) mds
US-2015344953-A1 · Dec 3, 2015 · US
Major assignees
Companies most often associated with this inventor's publications.
| Assignee | Patents |
|---|---|
| H Lee Moffitt Cancer Ct & Res | 29 |
| Anp Tech Inc | 1 |
| Univ South Florida | 1 |
Top CPC classifications
Most common classification codes across this inventor's patents.
| CPC | Patents |
|---|---|
| A61K45/06 | 13 |
| A61K38/00 | 12 |
| A61K31/454 | 11 |
| C12N2310/14 | 8 |
| A61K47/549 | 8 |